{
    "clinical_study": {
        "@rank": "51874", 
        "arm_group": [
            {
                "arm_group_label": "sequence I", 
                "arm_group_type": "Experimental", 
                "description": "10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)"
            }, 
            {
                "arm_group_label": "sequence II", 
                "arm_group_type": "Experimental", 
                "description": "bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)"
            }, 
            {
                "arm_group_label": "sequence III", 
                "arm_group_type": "Experimental", 
                "description": "placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) -  washout (7 days) - bambuterol 5mg (21 days)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, 3-crossover trial with a 7-days washout baseline period\n      followed by three treatment periods of 21-days each performed in patients with COPD.\n      Patients will be randomized to receive three treatments (bambuterol 10mg, bambuterol 5 mg\n      and placebo)."
        }, 
        "brief_title": "Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with COPD who meet the inclusion criteria will enter the 7-days washout baseline\n      period. After the baseline period, patients will be randomly assigned to one of the\n      following treatment sequences:\n\n        -  Sequence I: bambuterol 10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -\n           washout (7 days) - placebo (21 days);\n\n        -  Sequence II: bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) - washout\n           (7 days) - bambuterol 10mg (21 days) ;\n\n        -  Sequence III: placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout\n           (7 days) - bambuterol 5mg (21 days).\n\n      During the treatment period patients will record their adverse events and use of rescue\n      medication (Ipratropium bromide) in a diary. At each visit, pulmonary function tests will be\n      performed. At V2, V4 and V6, forced expiratory volume at one second (FEV1) and forced vital\n      capacity (FVC) are measured at following times: immediately before tablet treatment, and at\n      0.5, 1, 2, 3, 4, 6, 9, 12hrs after administration of tablets, FEV1 and FVC area under curve\n      (AUC) 0~12 hours will be analyzed. At V1, V3, V5 and V7, and FVC are measured a time in the\n      morning. Peak expiratory flow rate (PEFR) is measured by Mini-Wright peak flow meter in the\n      morning before treatments. All other data will be evaluated as safety status, and monitoring\n      of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  COPD, the disease is under a stable phase\n\n          -  Giving written informed consent\n\n          -  Age 40 - 80 years (both inclusive)\n\n          -  Chinese ethnicity\n\n          -  30% of predicated normal \u2264Post bronchodilator FEV1 \u2264 70% of predicated normal\n\n          -  Post bronchodilator FEV1/FVC \u2264 70% (Note: post bronchodilator FEV1 will be tested\n             20-30 minutes after Salbutamol is used (inhaled via metered dose inhaler (MDI) and\n             spacer).\n\n        Exclusion Criteria:\n\n          -  COPD acute exacerbation 4 weeks prior to the enrollment\n\n          -  Patients with a history of asthma, allergic rhinitis, atopy\n\n          -  Use of disallowed drugs\n\n          -  Clinically relevant abnormal laboratory values suggesting an undiagnosed disease\n             requiring further clinical evaluation (as assessed by the Investigator)\n\n          -  Severe psychiatric or neurological disorders\n\n          -  Congestive heart failure severity grade IV according to New York Heart Association\n             (NYHA)\n\n          -  Haemodynamically significant cardiac arrhythmias or heart valve deformations\n\n          -  CT or X-ray findings indicating an acute pulmonary disease other than COPD (e.g.\n             tuberculosis, severe bronchiectasis, tumors)\n\n          -  Severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus\n             erythematosus, progressive multifocal leukoencephalopathy)\n\n          -  Severe acute infectious diseases (e.g. tuberculosis or acute hepatitis)\n\n          -  Any diagnosis of a malignant disease (except basal cell carcinoma) within 5 years\n             before trial start\n\n          -  Alcohol or drug abuse within the past year\n\n          -  Suspected hypersensitivity to the Bambuterol or ingredients thereof, or any other\n             contraindication for the use thereof\n\n          -  Pregnancy, breast feeding, planned oocyte donation or oocyte implantation\n\n          -  Participation in another trial (use of investigational product) within 30 days\n             preceding the baseline visit V1 or re-entry of patients previously enrolled in this\n             trial\n\n          -  Suffering from any concomitant disease that might interfere with trial procedures or\n             evaluations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796730", 
            "org_study_id": "GIRDBAM201201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "sequence I", 
                    "sequence II", 
                    "sequence III"
                ], 
                "description": "Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.", 
                "intervention_name": "bambuterol", 
                "intervention_type": "Drug", 
                "other_name": "Bambec, KWD-2183"
            }, 
            {
                "arm_group_label": [
                    "sequence I", 
                    "sequence II", 
                    "sequence III"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bambuterol", 
                "Terbutaline"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "efficacy", 
            "safety", 
            "Bambuterol tablets", 
            "COPD"
        ], 
        "lastchanged_date": "September 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jpzhenggy@163.com", 
                    "last_name": "Jinping Zheng, professor", 
                    "phone": "862083062869"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510120"
                    }, 
                    "name": "Guangzhou Institution of Respiratory Disease (GIRD), The First Affiliated Hospital of Guangzhou Medical University"
                }, 
                "investigator": {
                    "last_name": "Jinping Zheng, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hxkcai@126.com", 
                    "last_name": "Shaoxi Cai, Professor", 
                    "phone": "61641575", 
                    "phone_ext": "8620"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510000"
                    }, 
                    "name": "Nanfang Hospital of Southern Medical University"
                }, 
                "investigator": {
                    "last_name": "Shaoxi Cai, Prefossor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zhaozw1963@163.com", 
                    "last_name": "Ziwen Zhao, Professor", 
                    "phone": "81048888", 
                    "phone_ext": "8620"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510000"
                    }, 
                    "name": "Guangzhou First Municipal People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Ziwen Zhao, professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 12-week, Double-blind, Multicenter, 3-crossover, Placebo Controlled and Randomized Trial to Investigate the Efficacy and Safety of 10mg and 5mg Bambuterol Tablets Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "other_outcome": [
            {
                "description": "\u2022difference of use of rescue medication (Ipratropium bromide) during the treatment period among 3 dose groups", 
                "measure": "use of rescue medication", 
                "safety_issue": "Yes", 
                "time_frame": "during  0 to 3week,4 to 7 week and 8 to 11 week"
            }, 
            {
                "description": "The Baseline Dyspnea Index (BDI) will be collected before each treatment period, ie. at visits of 2, 4, 6.\nTransition Dyspnoea Index (TDI) will be collected at the end of each treatment period, ie. at visits of 3, 5, 7.", 
                "measure": "The Baseline Dyspnea Index (BDI) and Transition Dyspnoea Index (TDI)", 
                "safety_issue": "No", 
                "time_frame": "BDI at 0, 4 and 8 week, TDI at 3, 7 and 11 week"
            }, 
            {
                "description": "Difference of frequency and severity of tremor, palpitation and other adverse events among 3 dose groups will be collected and analyzed during the whole study period.", 
                "measure": "Tremor, Palpitation", 
                "safety_issue": "Yes", 
                "time_frame": "up to 11 weeks"
            }, 
            {
                "description": "Electrocardiogram (ECG) will be assessed at all visits", 
                "measure": "electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "at -1,0,3,4,7,8,11 week"
            }
        ], 
        "overall_contact": {
            "email": "jpzhenggy@163.com", 
            "last_name": "Jinping Zheng, Professor", 
            "phone": "86-20-83062869"
        }, 
        "overall_contact_backup": {
            "email": "laile1986@163.com", 
            "last_name": "Le Lai, pharmacist", 
            "phone": "86-20-83062338"
        }, 
        "overall_official": {
            "affiliation": "Guagnzhou Institute of Respiratory Disease, First affiliated hospital of Guangzhou Medical University", 
            "last_name": "Jinping Zheng, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoints will be the difference in FEV1 as well as FVC between pre-treatment and post-treatment at respective treatment period (ie. Visit 2(0 week) and Visit 3(3 week), Visit 4 (4 week)and Visit 5(7 week), Visit 6 (8 week) and Visit 7(11 week)) .", 
            "measure": "the change in FEV1(L) and FVC(L)", 
            "safety_issue": "No", 
            "time_frame": "pre- and post-treatment during 0 to 3 week, 4 to 7 week  and 8 to 11 week"
        }, 
        "reference": [
            {
                "PMID": "9033440", 
                "citation": "McDonald CF, Pierce RJ, Thompson PJ, Allen D, Bowler S, Breslin AB, Bowes G, Saunders N, Murree-Allen K, Frith P, Musk AW. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction. J Asthma. 1997;34(1):53-9."
            }, 
            {
                "PMID": "10027655", 
                "citation": "Cazzola M, Calderaro F, Califano C, Di Pema F, Vinciguerra A, Donner CF, Matera MG. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease. Eur J Clin Pharmacol. 1999 Jan;54(11):829-33."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796730"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Affiliated Hospital of Guangzhou Medical University", 
            "investigator_full_name": "jingping Zheng", 
            "investigator_title": "Vice Director of Guangzhou Institution of Respiratory Disease", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC FEV1: 0-12h in V2 (0 week), V4 (4 week) and V6 (8 week),\nAUC FVC: 0-12h in V2 (0 week), V4 (4 week) and V6 (8 week),", 
                "measure": "difference of AUC(0-12h) FEV1(L) as well as AUC(0-12h) FVC(L) among 3 dose groups", 
                "safety_issue": "No", 
                "time_frame": "at 0, 4, 8 week"
            }, 
            {
                "description": "difference of Peak flow rate (PEFR) during the treatment period among 3 dose groups", 
                "measure": "change of PEFR(L/min)", 
                "safety_issue": "No", 
                "time_frame": "during 0 to 3 week, 4 to 7 week and 8 to 11 week"
            }
        ], 
        "source": "The First Affiliated Hospital of Guangzhou Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Nanfang Hospital of Southern Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangzhou First Municipal People\u2019s Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Guangzhou Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}